John Segreti to Staphylococcal Infections
This is a "connection" page, showing publications John Segreti has written about Staphylococcal Infections.
Connection Strength
1.369
-
Empirical therapy in Methicillin-resistant Staphylococcus Aureus infections: An Up-To-Date approach. J Infect Chemother. 2016 Jun; 22(6):351-9.
Score: 0.477
-
Empirical therapy for serious Gram-positive infections: making the right choice. Clin Microbiol Infect. 2009 Dec; 15 Suppl 6:5-10.
Score: 0.307
-
Antibiotic therapy of methicillin-resistant Staphylococcus aureus in critical care. Crit Care Clin. 2008 Apr; 24(2):249-60, vii-viii.
Score: 0.273
-
Prevalence of a Cefazolin Inoculum Effect Associated with blaZ Gene Types among Methicillin-Susceptible Staphylococcus aureus Isolates from Four Major Medical Centers in Chicago. Antimicrob Agents Chemother. 2018 08; 62(8).
Score: 0.140
-
Treatment outcomes with cefazolin versus oxacillin for deep-seated methicillin-susceptible Staphylococcus aureus bloodstream infections. Antimicrob Agents Chemother. 2015 Sep; 59(9):5232-8.
Score: 0.113
-
Daptomycin for the treatment of gram-positive bacteremia and infective endocarditis: a retrospective case series of 31 patients. Pharmacotherapy. 2006 Mar; 26(3):347-52.
Score: 0.059